

INTERNATIONAL SYMPOSIUM

SCIENTIFIC PROGRAMME

VENICE, MARCH 8th-10th, 2024

UNDER THE PATRONAGE OF







SIMIT Società Italiana di Malattie Infettive e Tropicali



RATIONALE

Innovation. This is the word that inspires the TOP5 Congress in Venice. This event is organized to find new solutions for different challenges in infectious diseases and to bring current global issues to the attention of institutions.

Nowadays, in the era of globalization, innovation in infectious diseases is crucial to find new weapons against several threats. The challenges in the treatment of infectious diseases will be discussed in a scientific and public debates. The following topics will be covered:

- 1. Antimicrobial resistant microrganisms. The global spread of multidrug resistant organisms (MDRO) causing severe infections in both the community and nosocomial setting is a threat for public health. Innovative strategies are needed to implement early diagnosis and optimal/appropriate use of new available antibiotics.
- COVID-19 is not over and frail patients continued to be at increased risk of severe outcomes subsequent to SARS CoV-2 infection. Implementation of new strategies (monoclonal antibodies, vaccines, antivirals) is crucial to prevent and treat COVID-19. New vaccine platforms represent innovative strategies that should be appropriately applied to the clinical setting.
- 3. HIV still represents an ongoing challenge. Increase in late presentation of HIV infection poses the scientific community in front of the need for implementation of pre-exposure prophylaxis, testing and early HIV infection diagnosis. Moreover, the complexity of HIV-positive people highlights the need for tailored therapeutic approaches.
- 4. Beyond the ambitious goal of HCV eradication, emergence of delta virus as cause of hepatitis and presence of coinfections (such as HIV and HBV) poses new challenges that should be addressed.
- 5. Fungi are evolving and new multidrug resistant species spread around the world. New antifungals are needed to overcome resistance in yeast and molds infections.

But what does "innovation" mean in these 5 field of Infectious Diseases? Innovation means "appropriate and rational use" of diagnostic methods, antimicrobials, Big Data and maching learning finalized to develop updated knowledge and new solutions for the treatment of Infectious Diseases in the modern era. These issues should be discussed with academicians, stakeholders, professionals and young researchers to share experiences and evidences and to have an unforgettable experience in Venice.

FIRST DAY - FRIDAY 8th MARCH MORNING SESSIONS

- 09:00-09:30 Registration of participants
- 09:30-09:40 Welcome to participants and Opening remarks Marco Falcone

SESSION I: DEBATE ON METHODOLOGY ON CLINICAL RESEARCH Chairs: Leonard Leibovici, Marco Falcone

- 09:40-10:00 The levels of evidence: the value of RCTs in infectious diseases Mical Paul
- 10:00-10:20 Target trial emulation: how to extrapolate data from the real world experience Joseph Ross
- 10:20-10:40 The Editor's choice: how to select relevant articles for my Journal Leonard Leibovici
- 10:40-11:10 ROUND TABLE WITH DISCUSSION: Exclusion criteria of RCTs and real life use of new antibiotics in critical patients: how to fill the gap? Discussant: **David Van Duin**
- 11:10-11:40 Coffee Break

SESSION II: DEVELOPMENT OF NEW DRUGS IN THE PANDEMIC ERA Chairs: Andrea Cossarizza, Andrea Gori

- 11:40-12:00 Al from bench to bedside to FDA approval: the story of baricitinib in the pandemic Justin Stebbing
- 12:00-12:20 Monoclonal antibodies for treating multidrug-resistant infections Rino Rappuoli
- 12:20-12:40 The Yin Yang of innate immunity and inflammation in infectious diseases Alberto Mantovani
- 12:40-13:15 Q&A session
- 13:15-14:30 Lunch



FIRST DAY - FRIDAY 8th MARCH AFTERNOON SESSIONS

14:30-15:00 LECTURE: Cardio-metabolic protection in people living with HIV • Esteban Martinez

SESSION III: BEYOND VIRAL SUPPRESSION: PRACTICAL MANAGEMENT OF CURRENT ISSUES RELATED TO HIV TREATMENT: INTERACTIVE SESSION

Chairs: Anna Maria Cattelan, Saverio Parisi

- 15:00-16:30 Presenters
 - Heavily treatment-experienced case Jovana Milic
 - Patients with high cardiovascular risk Silvia Nozza
 - Naïve Alberto Borghetti

- Over-65 • Emanuele Focà Discussant: Esteban Martinez

- 16:30-17:00 Coffee Break
- 17:00-17:30 LECTURE: Monotherapy or combination therapy for the treatment of carbapenem-resistant non-fermenting Gram negative bacilli: an overview in the era of novel antibiotics David Van Duin

SESSION IV: PRACTICAL MANAGEMENT OF DIFFICULT TO TREAT MULTIDRUG-RESISTANT BACTERIAL INFECTIONS: INTERACTIVE SESSION

- Chairs: Marco Falcone, Maddalena Giannella
- 17:30-19:00 MBL-producing Enterobacterales infections in special populations Giusy Tiseo
 - P. aeruginosa pneumonia Antonio Vena
 - A. baumanni bacteremic pneumonia Alessandro Russo
 - KPC infection with an uncommon resistance profile Michele Bartoletti Discussants: Mical Paul, David Van Duin
- 19:00 Closing remarks

SECOND DAY - SATURDAY 9th MARCH MORNING SESSIONS



09:00-09:30 LECTURE: Present and future of long-acting drugs in HIV-treatment • Chloe Orkin

SESSION I: ROUND TABLE - LIGHTS AND SHADOWS IN THE TREATMENT OF HIV-INFECTION Chairs: Gabriella D'Ettorre, Giulia Marchetti

- 09:30-09:50 Antiretroviral therapy of late presenters: when triple therapy is better? Cristina Mussini
- 09:50-10:10 Long-term efficacy of antiretroviral therapy: when dual therapy is better? Esteban Martinez
- 10:10-10:30 Learnings from the CAPELLA trial in HTE people living with HIV with multi-drug resistance Antonella Castagna
- 10:30-10:50 New therapeutics approach for Delta Hepatitis Maurizia Rossana Brunetto
- 10:50-11:10 Discussion Chloe Orkin, Carlo Torti
- 11:10-11:30 Coffee Break
- 11:30-12:00 LECTURE: Invasive mycoses and new resistance profiles: from yeast to invasive molds Patricia Muñoz

SESSION II: COVID-19 AND BEYOND

Chairs: Raffaele Bruno, Claudio M. Mastroianni

- 12:00-12:20 Prevention of Covid-19 infection in immunocompromized: what's new Giovanni Di Perri
- 12:20-12:40 Treatment of Covid-19: update on antivirals Ali Omrani
- 12:40-13:00 Treatment of frail patients with COVID-19: actual role of monoclonal antibodies Andrea Antinori
- 13:00-13:20 Antifungal therapy in critical patients with invasive mycoses: present and future Pierluigi Viale
- 13:20-13:30 Discussion Stefano Bonora, Patricia Muñoz
- 13:30-14:30 Lunch

SECOND DAY - SATURDAY 9th MARCH

AFTERNOON SESSIONS

14:30-15:00 OPENING LECTURE: Antimicrobial therapy of carbapenem-resistant Enterobacterales infections: present and future • Souha Kanj

SESSION III: ROUND TABLE - LIGHTS AND SHADOWS IN THE TREATMENT OF INFECTIONS BY MDR GRAM NEGATIVE BACILLI

Chairs: Francesco De Rosa, Mario Venditti

- 15:00-15:20 Colistin vs new beta-lactams/beta lactamases inhibitors: do we have the final word? Matteo Bassetti
- 15:20-15:40 HAP/VAP: which role of new antibiotics in improving outcomes? Pierre Tattevin
- 15:40-16:00 New drugs against Acinetobacter baumannii: going ahead or coming back? Marco Falcone
- 16:00-16:20 Treatment of metallo-beta lactamases producing Enterobacterales: an update David Paterson
- 16:20-16:40 Discussion Souha Kanj, Jason Pogue
- 16:40-17:00 Coffee Break

SESSIONE IV: EQUITÀ DELLE CURE ED ACCESSO ALL'INNOVAZIONE SCIENTIFICA IN MALATTIE INFETTIVE: SCIENZA, ISTITUZIONI E INDUSTRIA FARMACEUTICA A CONFRONTO (non-CME Session)

Introduzione • Marco Falcone, Sen. Adolfo Urso* (Ministro delle Imprese e del Made in Italy) On. Marcello Gemmato* (Sottosegretario alla Salute)

On. Alessio Butti (Sottosegretario di Stato alla Presidenza del Consiglio dei Ministri) TALK SHOW: conduce **Tonia Cartolano** (Sky tg24)

- 17:00-17:10 Antiobiotico-resistenza: iniziative del Ministero della Salute Francesco Vaia
- 17:10-17:20 Presentazione dell'Intergruppo Parlamentare Prevenzione e Controllo delle Malattie Infettive e Tropicali • Sen. Fausto Orsomarso
- 17:20-17:30 Investments in pre-clinical and clinical research for new antibiotics: lights and shadows Najy Alsayed**
- 17:30-17:40 Future strategies for prevention and treatment of acute and chronic infections Fabio Landazabal**
- 17:40-18:30 ROUND TABLE: intervengono Maurizio Amato, Frederico da Silva, Guido Di Donato, Francesca Patarnello, Andrea Pitrelli, Federico Serra, Carlo Signorelli, Serafino Sorrenti



Traduzione online su ZOOM

* In videocollegamento **Traduzione simultanea online da Inglese a Italiano

THIRD DAY - SUNDAY 10th MARCH MORNING SESSIONS



09:30-10:00 LECTURE: MRSA: an update on the perfect pathogen • Alex Soriano

SESSION I: PROS AND CONS DEBATE: INTERACTIVE SESSION Chairs: Marco Falcone, Francesco Menichetti

- 10:00-11:30 Monotherapy vs combination therapy for CRE infections Combination therapy • Jason Pogue Monotherapy • Marianna Meschiari
 - Short vs prolonged intravenous therapy in patients with bloodstream infections: When shortening therapy is possible • Dafna Yahav
 When shortening therapy is not recommended • Mario Tumbarello
 - Genotypic vs phenotypic approach in MDR infections
 Pros and cons of genotypic tests
 Gian Maria Rossolini
 Pros and cons of phenotypic tests
 Stefania Stefani

Discussants: Alex Soriano, Mario Tumbarello

11:30-12:00 Coffee Break

SESSION II: FUTURE RESEARCH IN INFECTIOUS DISEASES Chairs: Marco Falcone, Ivan Gentile

- 12:00-12:20 To bnAB or not to bnAB: broadly neutralizing against HIV-1 Steven Deeks
- 12:20-12:40 Monoclonal antibodies for Sars-CoV2 infection: present and future Davide Corti
- 12:40-13:00 Phages and microbiota Gina Suh
- 13:00-13:20 Q&A session
- 13:20-13:30 Closing remarks Marco Falcone
- 13:30-14:30 Light Lunch

FACULTY

Najy Alsayed - Menarini Group, Florence, Italy Maurizio Amato - Board Member Federchimica Assobiotec Andrea Antinori - INMI Spallanzani, Rome, Italy Michele Bartoletti - Humanitas University of Milan. Italy Matteo Bassetti - University of Genoa. Italy Stefano Bonora - University of Turin, Italy Alberto Borghetti - University of Pisa, Italy Maurizia Rossana Brunetto - University of Pisa, Italy Raffaele Bruno - University of Pavia, Italy Alessio Butti- Undersecretary to the Presidency of the Council of Ministers, Italy Tonia Cartolano - Journalist, Sky tg24, Italy Antonella Castagna - San Raffaele University of Milan, Italy Anna Maria Cattelan - University of Padua, Italy Davide Corti - HUMABS Biomed, Bellinzona, Swiss Andrea Cossarizza - University of Modena, Italy Frederico da Silva - Vice President & General Manager, Gilead Sciences Alessandro Russo - University of Catanzaro, Italy Francesco De Rosa - University of Turin, Italy Steven Deeks - University of California, San Francisco, USA Gabriella D'Ettorre - La Sapienza University of Rome, Italy Guido Di Donato - Italy Health and Value Senior Director, Pfizer Italy Giovanni Di Perri - University of Turin, Italy Marco Falcone - University of Pisa, Italy Emanuele Focà - University of Brescia, Italy Marcello Gemmato - Sottosegretario Ministry of Health, Italy Ivan Gentile - University of Naples, Italy Maddalena Giannella - University of Bologna, Italy Andrea Gori - L. Sacco Hospital, University of Milan, Italy Souha Kanj - American University of Beirut, Lebanon Fabio Landazabal - President of Farmindustria Prevention Group, Italy Leonard Leibovici - University of Tel Aviv, Israel Alberto Mantovani - Humanitas University of Milan, Italy Giulia Marchetti - University of Milan, Italy Esteban Martinez - University of Barcelona, Spain Claudio Maria Mastroianni - La Sapienza University of Rome, Italy Francesco Menichetti - G.I.S.A. President, Italy Marianna Meschiari - University of Modena, Italy Jovana Milic - University of Modena, Italy

Patricia Muñoz - Hospital Universitario G. Maranon, Madrid, Spain Cristina Mussini - University of Modena. Italy Silvia Nozza - San Raffaele University of Milan, Italy Ali Omrani - Quatar University, Doha, Qatar Fausto Orsomarso - Senator Italian Parliament Chloe Orkin - Queen Mary University of London, UK Saverio Parisi - University of Padua, Italy Francesca Patarnello - Vice President Market Access & Government Affairs, AstraZeneca Italy David Paterson - University of Singapore, Republic of Singapore Mical Paul - Rambam Health Care Campus, Haifa, Israel Andrea Pitrelli - Market Access & Government Affairs Head, Shionogi, Italy Jason Poque - University of Michigan College of Pharmacy, Ann Arbor, USA Rino Rappuoli - Biotechnopole Foundation of Siena, Italy Joseph Ross - Yale University, New Haven, CT, USA Gian Maria Rossolini - University of Florence, Italy Federico Serra - Segreteria Tecnica Intergruppo Parlamentare Prevenzione e Controllo delle Malattie Infettive e Tropicali Carlo Signorelli - President National Immunization Technical Advisory Group (NITAG) Alex Soriano - Hospital Clinic de Barcelona, University of Barcelona, Spain Serafino Sorrenti, Chief Innovation Officer, Dipartimento per la Trasformazione Digitale, Presidenza del Consiglio dei Ministri Justin Stebbing - Imperial College, London, UK Stefania Stefani - University of Catania, Italy Gina Suh - Mayo Clinic, Rochester, MN, USA Pierre Tattevin - Rennes University Hospital, Rennes, France Giusy Tiseo - University of Pisa, Italy Carlo Torti - Catholic University, Rome, Italy Mario Tumbarello - University of Siena, Italy Adolfo Urso - Minister of Enterprises and Made in Italy, Italy Francesco Vaia - Ministry of Health, Italy David Van Duin - UNC School of Medicine, Chapel Hill, NC, USA Antonio Vena - University of Genoa, Italy Mario Venditti - La Sapienza University of Rome, Italy Pierluigi Viale - University of Bologna, Italy Dafna Yahav - Rabin Medical Center, Beilinson Hospital, Petah-Tigva, Israel

GENERAL INFORMATION

PRESIDENT

Prof. Marco Falcone

Professor of Infectious Diseases Department of Clinical and Experimental Medicine University of Pisa, Azienda Ospedaliero-Universitaria Pisana, Pisa (Italy)

SCIENTIFIC SECRETARIAT

Prof. Cristina Mussini (Modena, Italy) Prof. Annamaria Cattelan (Padua, Italy) Dr. Giusy Tiseo (Pisa, Italy) Dr. Sandro Panese (Venice, Italy)

ORGANIZING SECRETARIAT AND CME PROVIDER



Nadirex International S.r.I. Via Riviera, 39 - 27100 Pavia Tel. +39.0382.525714 Fax. +39.0382.525736 <u>chiara.zoncada@nadirex.com</u> <u>www.nadirex.com</u>

MEETING VENUE

Hotel Monaco & Grand Canal San Marco 1332 - 30124 Venice

OFFICIAL LANGUAGE

The official language of the Meeting will be English.

TECHNICAL FACILITIES

Facilities will be available for computer presentations and overhead projections.

A Slide Center with PCs (Windows and Macintosh operating systems) will be available for Speakers to preview and finalize their presentations. Speakers are kindly requested to submit their presentations to the Slide Center technicians at least one hour before their talks.

ATTENDANCE CERTIFICATE

The attendance certificate will be provided at the end of the event.



NOTES

	 	· · · · · · · · · · · · · · · · · · ·
•••••	 	
•••••	 	
•••••	 	

With the unconditional educational contribution of

PLATINUM SPONSOR



GOLD SPONSORS



BRONZE SPONSORS

SHIONOGI

AstraZeneca

OTHER SPONSORS



